Helicobacter pylori public health implications

Helicobacter

Volumn 9, Issue SUPPL. 1, 2004, Pages 67-72

  Moayyedi, Paul ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Eradication therapy; Gastric adenocarcinoma; Helicobacter pylori; Prevention; Screening

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

CARCINOGENESIS; DYSPEPSIA; ERADICATION THERAPY; HEALTH SERVICE; HELICOBACTER INFECTION; HUMAN; MORTALITY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZATION; REVIEW; SCREENING; STOMACH CANCER; STOMACH MUCOSA;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MASS SCREENING; PEPTIC ULCER; STOMACH NEOPLASMS;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 4644234261     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1083-4389.2004.00250.x     Document Type: Review

References (57)

1. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
2. Horton R. Screening mammography - an overview revisited. Lancet 2001;358:1284-5.
3. Moayyedi P, Dixon MF. Significance of Helicobacter pylori infection and gastric cancer: implications for screening. Gastrointest Endosc Clin N Am 1997;7:47-64.
4. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
5. Arents NL, Thijs JC, van Zwet AA, Oudkerk PM, Gotz JM, van de Werf GT, et al. Approach to treatment of dyspepsia in primary care: a randomized trial comparing 'test-and-treat' with prompt endoscopy. Arch Intern Med, 2003;163: 1606-12.
6. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. (Update of Cochrane Database Syst Rev 2001 (3): CD001961; PMID: 11687004). Cochrane Database Syst Rev 2003: CD001961.
7. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
8. Kikuchi S, Crabtree JE, Forman D, Kurosawa M. Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research Group on Prevention of Gastric Carcinoma Among Young Adults. Am J Gastroenterol 1999;94:3455-9.
9. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14.
10. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long-term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.
11. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-14.
12. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
13. Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-10.
14. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
15. Parsonnet J, Forman D. Helicobacter pylori infection and gastric cancer - for want of more outcomes. JAMA 2004;291:244-5.
16. Forman D. Lessons from ongoing intervention studies. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1998;354-61.
17. Hunt RH. Will eradication of Helicobacter pylori infection influence the risk of gastric cancer? Aliment Pharmacol Ther 2004;20: in press.
18. Office of National Statistics. Causes of Death, England and Wales 2001. London, UK: Department of Health, 2004.
19. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; in press.
20. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2003: CD004062.
21. Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004;19:9-16.
22. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
23. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A, Hadziyannis SJ. Effect of Helicobacter pylori infection on risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med 2004;116:601-5.
24. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
25. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
26. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-35.
27. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
28. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016-21.
29. Paimela H, Paimela L, Myllykangas-Luosujarvi R, Kivilaakso E. Current features of peptic ulcer disease in Finland: incidence of surgery, hospital admissions and mortality for the disease during the past twenty-five years. Scand J Gastroenterol 2002;37:399-403.
30. Marshall JK, Collins SM, Gafni A. Demographic predictors of resource utilization for bleeding peptic ulcer disease: the Ontario GI Bleed Study. J Clin Gastroenterol 1999;29:165-70.
31. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21.
32. Moayyedi P, Decks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621-6.
33. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000;355: 1665-9.
34. Lane JA, Murray L, Egger M, et al. Effect of eradication of Helicobacter pylori infection in the community on the incidence of dyspepsia: The Bristol Helicobacter project. Gastroenterology 2002;122:A475.
35. Wildner-Christensen M, Moller HJ, Schaffalitzky De Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125:372-9.
36. Roderick P, Davies R, Raftery J, et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003;7: 1-86.
37. Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-68.
38. Axon A. Ethical issues in the management of Helicobacter pylori infection. Can J Gastroenterol 2003;17:62B-64B.
39. Edwards PJ, Hall DM. Screening, ethics, and the law. BMJ 1992;305:267-8.
40. Meystre-Agustoni G, Paccaud F, Jeannin A, Dubois-Arber F. Anxiety in a cohort of Swiss women participating in a mammographic screening programme. J Med Screen 2001;8:213-9.
41. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Medical 1997;337:441-6.
42. Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003;139: 483-7.
43. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003;326:737.
44. Raghunath A, Hungin AP, Wooff D, Childs S. The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis - a systematic review. Aliment Pharmacol Ther 2004;20: in press.
45. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
46. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of the effects of Helicobacter pylori infection and its eradication on heartburn and gastrooesophageal reflux: the Bristol Helicobacter Project. BMJ 2004;328:1417-9.
47. Delaney BC, Moayyedi P. Eradicating Helicobacter pylori does not increase symptoms of gastro-oesophageal reflux disease. BMJ 2004;328: 1388-9.
48. Axon AT. Personal view: to treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease - an alternative hypothesis. Aliment Pharmacol Ther 2004;19:253-61.
49. Chow WH, Blaser MJ, Blot WJ, et al. Inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-90.
50. Wu AH, Crabtree JE, Bernstein L, et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003;103:815-21.
51. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004;96:388-96.
52. Forman D, Graham DY. Review article: impact of Helicobacter pylori on society-role for a strategy of 'search and eradicate'. Aliment Pharmacol Ther 2004;19:17-21.
53. Ley C, Mohar A, Guarner J, et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomark Prev 2001; 10:107-12.
54. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125:1636-44.
55. Sullivan T, Ashbury FD, Fallone CA, et al. Helicobacter pylori and the prevention of gastric cancer. Can J Gastroenterol 2004;18:295-302.
56. Aaby P, Samb B, Simondon F, et al. Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal. Am J Epidemiol 1993;138:746-55.
57. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124:544-60.